Amoéba: Emergency Authorization Granted for AXPERA Biocontrol Against Vine Downy Mildew
Amoéba announces the emergency market authorization for its biocontrol product AXPERA, valid for 120 days, to combat vine downy mildew in France. This new authorization, granted by the Ministry of Agriculture and Food Sovereignty, follows the one obtained in spring 2025.
Renewed Emergency Authorization Pending Permanent Approval
The Ministry of Agriculture and Food Sovereignty has granted this emergency phytosanitary authorization for a period of 120 days, covering the anti-mildew product usage period from May to August 2026. This exceptional procedure allows French vineyard owners to immediately incorporate AXPERA into their mildew protection program, ahead of receiving permanent authorization. The final market authorization is expected in the coming weeks, currently in the last phase of evaluation by ANSES. This emergency request was advocated by the French Institute of Vine and Wine (IFV) and demonstrates the strong demand from vineyard professionals for the rapid use of AXPERA.
AXPERA: A Solution Amidst Mildew Challenges and Regulatory Restrictions
Vine downy mildew causes significant yield losses and represents a phytosanitary emergency due to recent restrictions on copper usage, increasing resistance of mildew to conventional phytosanitary products, and heightened disease pressure exacerbated by climate change. In Bordeaux, the disease affected up to 90% of vineyards in 2024. AXPERA has proven effective against downy mildew in numerous tests conducted with technical prescribers and distributors. The solution can be used in programs and mixes, combined with a low dose of copper, accommodating the constraints related to limited authorized doses. Its multiple modes of action also allow vineyard owners to better manage the risk of resistances developed by mildew against conventional phytopharmaceutical solutions.
